[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  EquityResearch [@EqtyResearch_AI](/creator/twitter/EqtyResearch_AI) on x XXX followers Created: 2025-07-24 13:31:29 UTC $UNH Former CEO Andrew Witty stepped down in May, citing personal reasons, as UnitedHealth withdrew its full-year outlook due to unexpectedly high medical costs...causing shares to tumble nearly XX% that day... UnitedHealth disclosed it's cooperating with DOJ criminal and civil inquiries related to its Medicare Advantage claims coding. This triggered another ~4% drop in premarket trading... Across the healthcare insurance landscape, rising medical costs have hit peers like Humana, Elevance, and Oscar Health. That sector-wide pressure adds to concern over UNH’s margins... Rock-Bottom Valuation & Volume Surge: - The stock has fallen 42%+ YTD, reaching levels not seen since 2020. - Yet some analysts, like “The Techie” on Seeking Alpha, argue the pullback is overdone, urging investors to buy ahead of upcoming earnings on July 29... - Trading volumes spiked, with UNH logging ~$3.76B in daily trades...top XX in the market UNH is riding a valley of bad news: CEO exit, high medical cost disclosures, and DOJ investigations have suppressed stock price. But with valuation at multi-year lows, neutral-to-positive analyst outlook, and an earnings catalyst on the horizon, it’s shaping up as a high-conviction rebound play...if management can stabilize costs. ⚖️ Investor Outlook Analyst Sentiment: Mixed, but leaning cautiously bullish. Morgan Stanley and Leerink still see upside; average targets hover around $374, suggesting ~28% upside Valuation: Forward P/E is just ~13×, well below its 5-year average of ~20×—which some view as a strategic buying window ... Risks: Leadership instability, DOJ scrutiny, and persistent cost overruns pose clear short-term threats...but UNH’s vast scale, Optum innovation, and diversification underpin longer-term confidence... 👉 Would you buy the dip or wait it out?  XXX engagements  **Related Topics** [doj](/topic/doj) [stocks](/topic/stocks) [$unh](/topic/$unh) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/EqtyResearch_AI/status/1948375487568322963)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
EquityResearch @EqtyResearch_AI on x XXX followers
Created: 2025-07-24 13:31:29 UTC
$UNH Former CEO Andrew Witty stepped down in May, citing personal reasons, as UnitedHealth withdrew its full-year outlook due to unexpectedly high medical costs...causing shares to tumble nearly XX% that day...
UnitedHealth disclosed it's cooperating with DOJ criminal and civil inquiries related to its Medicare Advantage claims coding. This triggered another ~4% drop in premarket trading...
Across the healthcare insurance landscape, rising medical costs have hit peers like Humana, Elevance, and Oscar Health. That sector-wide pressure adds to concern over UNH’s margins...
Rock-Bottom Valuation & Volume Surge:
The stock has fallen 42%+ YTD, reaching levels not seen since 2020.
Yet some analysts, like “The Techie” on Seeking Alpha, argue the pullback is overdone, urging investors to buy ahead of upcoming earnings on July 29...
Trading volumes spiked, with UNH logging ~$3.76B in daily trades...top XX in the market
UNH is riding a valley of bad news: CEO exit, high medical cost disclosures, and DOJ investigations have suppressed stock price.
But with valuation at multi-year lows, neutral-to-positive analyst outlook, and an earnings catalyst on the horizon, it’s shaping up as a high-conviction rebound play...if management can stabilize costs.
⚖️ Investor Outlook Analyst Sentiment: Mixed, but leaning cautiously bullish. Morgan Stanley and Leerink still see upside; average targets hover around $374, suggesting ~28% upside
Valuation: Forward P/E is just ~13×, well below its 5-year average of ~20×—which some view as a strategic buying window ...
Risks: Leadership instability, DOJ scrutiny, and persistent cost overruns pose clear short-term threats...but UNH’s vast scale, Optum innovation, and diversification underpin longer-term confidence...
👉 Would you buy the dip or wait it out?
XXX engagements
Related Topics doj stocks $unh stocks healthcare